GentiBio

Learn more about the POLARIS Study: polarisstudy.com

Kicking off tomorrow, GentiBio joins the AAI Conference to present our latest research data and insights. For full event details, please visit the press release here: gentibio.com/press_releases… #2026AAI #immunology #biotech #AmericanAssociationofImmunologists #Treg #CellTherapy

✔️Christopher Moore, Director, will be presenting “An Allogeneic CD19-Targeted Engineered Treg Approach for Treating B Cell-Mediated Autoimmune Diseases” on Saturday, April 18 (2:30 PM)

✔️ Victoria DeVault-Nelson, Associate Director, will be presenting “Comprehensive Biomarker Strategy to Monitor GNTI-122, an Engineered Regulatory T Cell Therapy in Clinical Development to Treat Type 1 Diabetes” on Saturday, April 18 (2:30 PM)

We are excited to be presenting at the upcoming #AAI2026 next week and connecting with colleagues across the immunology community. Our team will be sharing both seminar presentations and poster sessions highlighting our latest advances in engineered regulatory T cell therapies.

Read the full announcement: prnewswire.com/news-releases/…

GentiBio has successfully dosed the first participant in our clinical trial, the POLARIS Study, for adults recently diagnosed with Type 1 Diabetes (T1D). We are incredibly proud to announce this meaningful milestone for our team and community.

Learn more about the POLARIS Study: polarisstudy.com

GentiBio announces preclinical data at #ESGCT showing antigen-specific engineered #Tregs suppressing pancreatic inflammation and potential utility for treatment and prevention of clinical type 1 #diabetes (#T1D)." Click here to learn more: gentibio.com/press_releases…

We’re thrilled to announce our collaboration with global leader @bmsnews to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD. Read more here: bit.ly/3zJmigp

Genti is happy to announce that Neely Mozaffarian, MD, PhD has joined as Chief Medical Officer. Please join us in welcoming Neely! prnewswire.com/news-releases/…

We are excited to welcome our new CFO Chuck Silberstein to the team! prnewswire.com/news-releases/…

GentiBio is thrilled to share a perspective piece on how to succeed. Our CEO, Adel Nada, discusses, in order to succeed you need to prepare for failure and the importance of learning from mistakes. Enjoy! rapport.bio/all-stories/to…

GentiBio is excited to welcome 2022 and honored to be part of this list biospace.com/article/top-li…

Congratulations to our fellow @NewEnglandVC #NEVYs21 Nominees –we're so proud to be nominated alongside this group of superheroes! December 2nd we will be at the @HOBBoston for the 9th Annual NEVY Awards, and we hope you’ll join us! thenevys.com

Proud to be working with Seattle Children's in the Treg cell therapy space! @seattlechildren pulse.seattlechildrens.org/seattle-childr…

Following the successful closing of a $157 million Series A, @GentiBio will continue to develop and advance its potential functional cure for #T1D to the clinic, alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. gentibio.com